Results 101 to 110 of about 65,110 (152)

Interactions of a Glucagon-like peptide 1 and a Glucagon-like peptide 1 analogue, liraglutide, with the endogenous receptor

, 2015
Frederiksen, Tine Maja; id_orcid 0000-0003-2566-8448, Harris, Pernille, Bukrinski, Jens T., Peters, Günther H.J.; id_orcid 0000-0001-9754-2663   +3 more
openaire   +1 more source

Glucagon-Like Peptide-1 Receptor Agonists and Fragility Fracture Risk in Type 2 Diabetes.

JAMA Netw Open
Hamad CD, Wiener J, Golzar A, Kaur H, Henein C, Kittredge AP, Su G, Kaelber DC, Chan L, Yeaman MR, Adams JS, Bernthal NM, Sheppard WL.   +12 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Glucagon-Like Peptide-1 Receptor Agonists

Reactions Weekly
Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs ...
Heather P. Whitley, Jennifer M. Trujillo
  +12 more sources

Overview of Glucagon-like Peptide-1 Receptor Agonists

Home Healthcare Now, 2015
Type 2 diabetes mellitus is an increasingly prevalent disease in the United States and globally. Multiple pharmacologic therapies are typically required over time to achieve and maintain target blood glucose levels. When first-line oral medications such as metformin (Glucophage) are not effective in achieving desired glycosylated hemoglobin (HbA1C ...
Laura, Steadman, Joan S, Grant, Lucinda J, Graven   +2 more
openaire   +2 more sources

Glucagon-like peptide-1 receptor action in the vasculature

Peptides, 2019
Glucagon-like peptide-1 receptor (GLP-1R) agonists augment insulin secretion and are thus used clinically to improve glycemia in subjects with type 2 diabetes (T2D). As recent data reveal marked improvements in cardiovascular outcomes in T2D subjects treated with the GLP-1R agonists liraglutide and semaglutide in the LEADER and SUSTAIN-6 clinical ...
Malak Almutairi, Rami Al Batran, John R. Ussher   +2 more
openaire   +2 more sources

Glucagon-like Peptide-1 Receptor Agonists

2021
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) have been used to treat patients with type 2 diabetes mellitus (T2DM) since exenatide, the first GLP-1RA, was approved in 2005. GLP-1 is a peptide hormone secreted by L cells of the small intestine in response to nutrients.
Ja Young Jeon, Hae Jin Kim
openaire   +1 more source

Obesity and Glucagon-Like Peptide-1 Receptor Agonists

JAMA
This Viewpoint discusses factors associated with the prevalence of obesity worldwide and whether the novel glucagon-like peptide-1 receptor agonists (GLP-1) can help unlock a health systems response to the obesity pandemic.
Francesca, Celletti, Francesco, Branca, Jeremy, Farrar   +2 more
openaire   +2 more sources